# CALGB 50303 (NCT00118209)

> Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

No report yet. It can be ordered.

- Drugs tested: DA-EPOCH-R
- Indication: untreated diffuse large B-cell lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00118209
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Alliance for Clinical Trials in Oncology
- Conditions: Large B Cell Lymphoma
- Interventions: rituximab; cyclophosphamide; doxorubicin; vincristine; prednisone; etoposide; filgrastim; pegfilgrastim
- Enrollment: 524
- Primary outcome: Progression-Free Survival Rate at 2 and 5 Years

## Indexed commentary on CALGB 50303 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 15 posts on X
- 2 podcast episodes

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=calgb-50303-nct00118209

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00118209", "email": "<work email>"}; the inbox owner confirms by the emailed link.